Trimetazidine Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antianginal Agent
Subclass
Metabolic Modulator (Fatty Acid Oxidation Inhibitor)
Speciality
Cardiology
Schedule (India)
Schedule H
Routes
Oral
Formulations
- Tablets (Immediate-release): 20 mg
- Tablets (Modified-release): 35 mg
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Chronic Stable Angina Pectoris (Adjunctive Therapy)
⚠️ Not for monotherapy — Always use as add-on to conventional antianginal agents (beta-blockers, calcium channel blockers, nitrates)
Immediate-Release Formulation (20 mg tablet):
| Parameter | Dose |
|---|---|
|
Starting dose
|
20 mg orally three times daily with meals |
|
Titration
|
Not applicable — fixed dosing regimen |
|
Usual maintenance dose
|
60 mg/day in three divided doses |
|
Maximum dose
|
60 mg/day |
Modified-Release Formulation (35 mg MR tablet):
| Parameter | Dose |
|---|---|
|
Starting dose
|
35 mg orally twice daily (morning and evening with meals) |
|
Titration
|
Not applicable — fixed dosing regimen |
|
Usual maintenance dose
|
70 mg/day in two divided doses |
|
Maximum dose
|
70 mg/day |
Clinical Notes:
- Must be taken with food to improve absorption
- Does not affect heart rate or blood pressure — hemodynamically neutral
- Not effective for acute angina attacks — no rescue use
- Mechanism: Shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation, improving myocardial efficiency under ischaemic conditions
- Benefits typically seen after 2–4 weeks of regular use
- Particularly useful when beta-blockers or CCBs are contraindicated, poorly tolerated, or provide inadequate symptom control
Secondary Indications – Adults (Off-label)
| Indication | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|
|
Tinnitus and Vertigo of Vascular/Ischaemic Origin (OFF-LABEL)
|
20 mg orally twice to three times daily OR 35 mg MR twice daily | 2–3 months trial; discontinue if no benefit | ENT specialist recommended | Indian specialist practice; limited controlled trial data |
|
Chorioretinal Disorders with Vascular Component (including Retinitis Pigmentosa) (OFF-LABEL)
|
35 mg MR orally twice daily | Long-term as tolerated | Specialist only (Ophthalmology) | Limited evidence; used in some Indian ophthalmic protocols |
|
Heart Failure with Reduced Ejection Fraction (HFrEF) — Adjunct (OFF-LABEL)
|
35 mg MR orally twice daily | Long-term | Specialist only (Cardiology) | Some RCTs suggest improvement in exercise capacity; not standard practice; Indian Heart Failure Society does not include as routine recommendation |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
Not applicable — no approved paediatric indications in India.
Secondary Indications – Paediatrics (Off-label)
Not recommended — safety and efficacy not established in patients below 18 years of age.
Age Restriction:
- Not recommended in children or adolescents under 18 years
- Off-label use is discouraged due to complete lack of paediatric pharmacokinetic and safety data
- Use only under exceptional circumstances with specialist supervision (e.g., rare paediatric vasculopathies)
Renal Adjustments
| eGFR (mL/min/1.73 m²) | Recommendation |
|---|---|
|
≥60
|
No dose adjustment required |
|
30–59
|
Use with caution; consider reduced dosing (35 mg once daily or 20 mg twice daily); monitor for adverse effects |
|
<30
|
Avoid — insufficient clearance data; increased risk of accumulation and adverse effects
|
|
Haemodialysis
|
Avoid — no data on dialysability; likely not removed effectively |
Additional Notes:
- Trimetazidine is predominantly renally excreted
- Assess renal function (serum creatinine, eGFR) before initiating therapy
Hepatic adjustment
Contraindications
- Known hypersensitivity to trimetazidine dihydrochloride or any excipients
- Parkinson's disease
- Parkinsonian symptoms (tremor, rigidity, akinesia, bradykinesia)
- Restless legs syndrome
- Other movement disorders
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
Cautions
- Elderly patients (≥65 years) — significantly increased risk of movement disorders; careful neurological assessment required before and during treatment
- Moderate renal impairment (eGFR 30–59) — dose reduction may be needed
- History of extrapyramidal symptoms or falls
- Concurrent use with dopamine antagonists (may increase risk of movement disorders)
- Not to be used for acute angina treatment or as initial therapy for unstable angina/MI
- Patients should be informed to report any movement abnormalities immediately
Pregnancy
| Parameter | Information |
|---|---|
|
Overall Safety
|
Safety in pregnancy not established; limited human data |
|
Risk
|
Unknown; no adequate controlled studies in pregnant women |
|
Preferred Alternatives
|
Unidentified |
|
When Use May Be Justified
|
Only if no suitable alternative and benefit clearly outweighs potential risk; requires specialist cardiology and obstetric input |
|
Monitoring
|
Fetal growth monitoring if used; maternal symptom assessment |
Lactation
| Parameter | Information |
|---|---|
|
Compatibility
|
Not recommended — insufficient data on excretion in human breast milk |
|
Expected Drug Level in Milk
|
Unknown; likely low based on physicochemical properties |
|
Preferred Alternatives
|
Better-studied antianginal agents (beta-blockers like metoprolol) if required |
|
Infant Monitoring
|
Not applicable — advised to avoid use during breastfeeding |
|
Recommendation
|
Avoid breastfeeding during treatment or avoid drug during breastfeeding |
Elderly
| Parameter | Recommendation |
|---|---|
|
Starting dose
|
Use lower end of dosing range; consider starting with 35 mg once daily (MR formulation) or 20 mg twice daily (IR formulation) |
|
Titration
|
Titrate slowly to full dose based on tolerability over 1–2 weeks |
|
Increased Risks
|
Extrapyramidal symptoms (tremor, rigidity, gait disturbance), falls, reversible Parkinsonism |
|
Additional Precautions
|
Assess baseline neurological status (gait, tremor, rigidity) before initiation; regular neurological review every 6 months; assess renal function before and during therapy; discontinue immediately if movement disorders develop |
Major drug interactions
| Interacting Drug | Mechanism | Effect | Management |
|---|---|---|---|
|
Dopamine Antagonists (metoclopramide, prochlorperazine, haloperidol, risperidone)
|
Additive dopamine blockade | Increased risk of extrapyramidal symptoms and Parkinsonism | Avoid combination, especially in elderly; if essential, monitor closely for movement disorders |
|
Levodopa / Dopamine Agonists
|
Pharmacodynamic antagonism at dopaminergic pathways | Potential worsening of Parkinsonian symptoms; reduced efficacy of dopaminergic therapy |
Contraindicated in patients with Parkinson's disease or on antiparkinsonian drugs
|
Moderate drug interactions
| Interacting Drug | Effect | Management |
|---|---|---|
|
Beta-blockers, Calcium Channel Blockers, Nitrates
|
Additive antianginal effect; theoretical synergy | Generally beneficial combination; intended use; monitor for symptomatic hypotension if adding nitrates |
|
Antihypertensives (ACE inhibitors, ARBs, diuretics)
|
Potential additive hypotensive effects (though trimetazidine is haemodynamically neutral) | Monitor blood pressure; unlikely to be clinically significant |
|
Opioid Analgesics
|
Additive sedation in elderly | Use with caution in elderly; monitor for excessive sedation |
|
CNS-active Drugs (antipsychotics, antidepressants with extrapyramidal potential)
|
Additive risk of tremor or extrapyramidal symptoms | Monitor neurological status |
Note: Trimetazidine has no significant CYP450-mediated interactions; drug interaction profile is relatively limited.
Common Adverse effects
- Gastrointestinal disturbance (nausea, vomiting, dyspepsia, abdominal pain)
- Dizziness
- Headache
- Asthenia, fatigue
- Rash, pruritus
- Somnolence
Serious Adverse effects
| Adverse Effect | Clinical Action |
|---|---|
|
Extrapyramidal Symptoms (tremor, rigidity, bradykinesia, gait instability) — dose-dependent and more common in elderly
|
Discontinue immediately; symptoms usually reversible within 4 months of stopping; refer to neurology if symptoms persist |
|
Reversible Parkinsonism
|
Discontinue immediately; most cases resolve after stopping drug; neurology consultation recommended |
|
Severe Hypersensitivity Reactions (angioedema, anaphylaxis — rare)
|
Discontinue permanently; emergency management |
|
Thrombocytopenia (very rare)
|
Monitor platelet count; discontinue if significant; haematology referral |
|
Agranulocytosis (very rare)
|
Discontinue immediately; haematology referral; supportive care |
|
Fixed Drug Eruption (rare)
|
Discontinue; dermatology consultation |
Monitoring requirements
| Timing | Parameters |
|---|---|
|
Baseline
|
Renal function (serum creatinine, eGFR); neurological examination (gait assessment, tremor evaluation, rigidity); history of movement disorders |
|
After initiation (4–8 weeks)
|
Symptom response (angina frequency, exercise tolerance); neurological status (any new tremor, gait difficulty, stiffness); tolerability assessment |
|
Long-term (every 6–12 months)
|
Neurological examination (especially in elderly — screen for extrapyramidal symptoms); renal function (annually or sooner if elderly or CKD); reassess need for continued therapy |
|
If movement disorders develop
|
Discontinue immediately; reassess; neurology referral if symptoms persist beyond 4 months |
Brands in India
Modified-Release (35 mg):
- Vastarel MR™ (Serdia/Servier)
- Flavedon MR™ (Serdia)
- Trimetazidine MR™ (Various)
- Carvidon MR™ (Sun Pharma)
- Trimet MR™
Immediate-Release (20 mg):
- Trimetazidine™ (Generic — various manufacturers)
- Trimet™
- Carvidon™
Note: Modified-release 35 mg formulation is more commonly prescribed due to twice-daily dosing convenience. Fixed-dose combinations are not commonly available.
Price range (INR)'
| Formulation | Price Range | Notes |
|---|---|---|
| 20 mg IR tablet | ₹3–₹6 per tablet | Less commonly used |
| 35 mg MR tablet | ₹7–₹12 per tablet | Most commonly prescribed formulation |
Regulatory: Not listed under NLEM 2022; not under NPPA price control; prices vary by brand and region
Clinical pearls
- Adjunctive therapy only — Trimetazidine is never first-line or monotherapy for angina; always add to beta-blockers, CCBs, or nitrates when these provide inadequate symptom control or are limited by adverse effects
- Haemodynamically neutral — Does not affect heart rate or blood pressure; particularly useful in patients with hypotension or bradycardia where beta-blockers or CCBs are problematic
- Parkinsonism screening is essential — Always screen for pre-existing movement disorders before starting; contraindicated in Parkinson's disease; risk is dose-dependent and highest in elderly
- Elderly require special attention — Start at lower doses; monitor neurological status regularly; discontinue immediately if tremor, gait disturbance, or rigidity develops — symptoms are usually reversible
- Renal function determines eligibility — Avoid in severe renal impairment (eGFR <30); reduce dose in moderate impairment; check eGFR before and during therapy
- No acute benefit — Does not relieve acute angina attacks; patients must continue to use short-acting nitrates (GTN sublingual) for breakthrough symptoms
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.